Algeria

Algeria

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.44 (2.04 - 2.84) 2019 Modelled IHME
2.46 (2.07 - 2.86) 2018 Modelled IHME
2.5 (2.09 - 2.94) 2017 Modelled IHME
2.58 (2.15 - 3.01) 2016 Modelled IHME
2.66 (2.20 - 3.10) 2015 Modelled IHME
2.72 (2.26 - 3.17) 2014 Modelled IHME
2.77 (2.32 - 3.23) 2013 Modelled IHME
2.81 (2.38 - 3.28) 2012 Modelled IHME
2.86 (2.39 - 3.33) 2011 Modelled IHME
2.91 (2.42 - 3.40) 2010 Modelled IHME
2.96 (2.47 - 3.46) 2009 Modelled IHME
3.02 (2.52 - 3.52) 2008 Modelled IHME
3.07 (2.55 - 3.59) 2007 Modelled IHME
3.13 (2.60 - 3.66) 2006 Modelled IHME
3.18 (2.64 - 3.75) 2005 Modelled IHME
3.24 (2.69 - 3.80) 2004 Modelled IHME
3.31 (2.74 - 3.89) 2003 Modelled IHME
3.37 (2.78 - 3.96) 2002 Modelled IHME
3.43 (2.82 - 4.05) 2001 Modelled IHME
3.47 (2.82 - 4.11) 2000 Modelled IHME
3.51 (2.86 - 4.16) 1999 Modelled IHME
3.54 (2.87 - 4.19) 1998 Modelled IHME
3.57 (2.88 - 4.23) 1997 Modelled IHME
3.59 (2.89 - 4.28) 1996 Modelled IHME
3.61 (2.90 - 4.30) 1995 Modelled IHME
3.63 (2.92 - 4.32) 1994 Modelled IHME
3.65 (2.95 - 4.35) 1993 Modelled IHME
3.67 (2.96 - 4.36) 1992 Modelled IHME
3.68 (2.97 - 4.37) 1991 Modelled IHME
3.7 (2.97 - 4.40) 1990 Modelled IHME
1.75 (1.23 - 2.43) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.27 (0.19 - 0.37) 2019 Modelled IHME
0.3 (0.21 - 0.40) 2018 Modelled IHME
0.31 (0.22 - 0.42) 2017 Modelled IHME
0.32 (0.22 - 0.41) 2016 Modelled IHME
0.32 (0.22 - 0.42) 2015 Modelled IHME
0.31 (0.22 - 0.40) 2014 Modelled IHME
0.3 (0.21 - 0.39) 2013 Modelled IHME
0.29 (0.20 - 0.38) 2012 Modelled IHME
0.28 (0.20 - 0.37) 2011 Modelled IHME
0.28 (0.19 - 0.36) 2010 Modelled IHME
0.29 (0.21 - 0.39) 2009 Modelled IHME
0.34 (0.24 - 0.44) 2008 Modelled IHME
0.41 (0.29 - 0.53) 2007 Modelled IHME
0.5 (0.37 - 0.65) 2006 Modelled IHME
0.6 (0.44 - 0.79) 2005 Modelled IHME
0.86 (0.64 - 1.11) 2004 Modelled IHME
1.31 (0.97 - 1.69) 2003 Modelled IHME
1.82 (1.35 - 2.36) 2002 Modelled IHME
2.25 (1.66 - 2.91) 2001 Modelled IHME
2.45 (1.79 - 3.19) 2000 Modelled IHME
2.5 (1.80 - 3.24) 1999 Modelled IHME
2.53 (1.81 - 3.28) 1998 Modelled IHME
2.55 (1.81 - 3.31) 1997 Modelled IHME
2.57 (1.81 - 3.37) 1996 Modelled IHME
2.6 (1.80 - 3.39) 1995 Modelled IHME
2.62 (1.82 - 3.41) 1994 Modelled IHME
2.64 (1.84 - 3.43) 1993 Modelled IHME
2.66 (1.89 - 3.46) 1992 Modelled IHME
2.69 (1.93 - 3.49) 1991 Modelled IHME
2.71 (1.97 - 3.53) 1990 Modelled IHME
0.22 (0.12 - 0.34) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
34 (26 - 44) 2019 Modelled IHME
34 (26 - 44) 2018 Modelled IHME
34 (26 - 44) 2017 Modelled IHME
34 (27 - 44) 2016 Modelled IHME
34 (27 - 44) 2015 Modelled IHME
35 (27 - 45) 2014 Modelled IHME
35 (27 - 45) 2013 Modelled IHME
36 (28 - 46) 2012 Modelled IHME
36 (28 - 46) 2011 Modelled IHME
36 (29 - 47) 2010 Modelled IHME
36 (29 - 47) 2009 Modelled IHME
37 (29 - 47) 2008 Modelled IHME
37 (29 - 47) 2007 Modelled IHME
37 (29 - 47) 2006 Modelled IHME
37 (29 - 47) 2005 Modelled IHME
37 (29 - 47) 2004 Modelled IHME
37 (29 - 47) 2003 Modelled IHME
37 (29 - 47) 2002 Modelled IHME
37 (29 - 47) 2001 Modelled IHME
37 (29 - 47) 2000 Modelled IHME
37 (29 - 47) 1999 Modelled IHME
37 (29 - 47) 1998 Modelled IHME
37 (29 - 47) 1997 Modelled IHME
37 (29 - 47) 1996 Modelled IHME
37 (29 - 47) 1995 Modelled IHME
37 (29 - 47) 1994 Modelled IHME
37 (29 - 47) 1993 Modelled IHME
37 (29 - 47) 1992 Modelled IHME
37 (29 - 47) 1991 Modelled IHME
37 (29 - 47) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
99 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
97 2006 Survey/reported WHO/UNICEF
97 2005 Survey/reported WHO/UNICEF
97 2004 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
91 2018 Survey/reported WHO/UNICEF
91 2017 Survey/reported WHO/UNICEF
91 2016 Survey/reported WHO/UNICEF
95 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
95 2013 Survey/reported WHO/UNICEF
95 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
95 2010 Survey/reported WHO/UNICEF
94 2009 Survey/reported WHO/UNICEF
91 2008 Survey/reported WHO/UNICEF
90 2007 Survey/reported WHO/UNICEF
80 2006 Survey/reported WHO/UNICEF
83 2005 Survey/reported WHO/UNICEF
81 2004 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2001
Eligible for HBV generic medicines
HBV National Action Plan
HBV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.63 (1.32 - 2.03) 2019 Modelled IHME
1.62 (1.31 - 1.99) 2018 Modelled IHME
1.61 (1.29 - 1.99) 2017 Modelled IHME
1.58 (1.29 - 1.94) 2016 Modelled IHME
1.55 (1.27 - 1.90) 2015 Modelled IHME
1.55 (1.27 - 1.90) 2014 Modelled IHME
1.54 (1.26 - 1.89) 2013 Modelled IHME
1.54 (1.25 - 1.89) 2012 Modelled IHME
1.53 (1.25 - 1.89) 2011 Modelled IHME
1.53 (1.24 - 1.89) 2010 Modelled IHME
1.52 (1.23 - 1.88) 2009 Modelled IHME
1.51 (1.23 - 1.87) 2008 Modelled IHME
1.51 (1.22 - 1.87) 2007 Modelled IHME
1.5 (1.21 - 1.87) 2006 Modelled IHME
1.49 (1.21 - 1.87) 2005 Modelled IHME
1.49 (1.21 - 1.86) 2004 Modelled IHME
1.49 (1.21 - 1.85) 2003 Modelled IHME
1.48 (1.21 - 1.84) 2002 Modelled IHME
1.48 (1.20 - 1.83) 2001 Modelled IHME
1.48 (1.20 - 1.82) 2000 Modelled IHME
1.48 (1.20 - 1.83) 1999 Modelled IHME
1.47 (1.19 - 1.81) 1998 Modelled IHME
1.47 (1.19 - 1.81) 1997 Modelled IHME
1.47 (1.19 - 1.81) 1996 Modelled IHME
1.47 (1.18 - 1.82) 1995 Modelled IHME
1.47 (1.19 - 1.82) 1994 Modelled IHME
1.47 (1.19 - 1.83) 1993 Modelled IHME
1.48 (1.19 - 1.84) 1992 Modelled IHME
1.48 (1.20 - 1.85) 1991 Modelled IHME
1.49 (1.20 - 1.88) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.4 (0.20 - 2.50) 2014 Modelled Gower et al, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
37 (28 - 46) 2019 Modelled IHME
37 (28 - 46) 2018 Modelled IHME
37 (28 - 46) 2017 Modelled IHME
37 (28 - 46) 2016 Modelled IHME
37 (28 - 46) 2015 Modelled IHME
37 (28 - 46) 2014 Modelled IHME
37 (27 - 45) 2013 Modelled IHME
37 (27 - 45) 2012 Modelled IHME
36 (27 - 45) 2011 Modelled IHME
36 (27 - 45) 2010 Modelled IHME
36 (27 - 45) 2009 Modelled IHME
36 (27 - 45) 2008 Modelled IHME
36 (27 - 45) 2007 Modelled IHME
36 (27 - 45) 2006 Modelled IHME
36 (27 - 45) 2005 Modelled IHME
36 (27 - 45) 2004 Modelled IHME
36 (27 - 46) 2003 Modelled IHME
36 (27 - 45) 2002 Modelled IHME
36 (27 - 45) 2001 Modelled IHME
36 (27 - 45) 2000 Modelled IHME
36 (27 - 45) 1999 Modelled IHME
36 (27 - 45) 1998 Modelled IHME
36 (27 - 45) 1997 Modelled IHME
36 (27 - 45) 1996 Modelled IHME
36 (27 - 45) 1995 Modelled IHME
36 (26 - 45) 1994 Modelled IHME
35 (26 - 44) 1993 Modelled IHME
35 (26 - 44) 1992 Modelled IHME
35 (26 - 44) 1991 Modelled IHME
35 (26 - 44) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2001
Eligible for HBV generic medicines
HBV National Action Plan
HBV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)

Overview

HBV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.44 (%)
2019
(2.04 - 2.84(%))
IHME
HCV (RNA/cAg+)
1.63 (%)
2019
(1.32 - 2.03(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
1,132
2019
(805 - 1,568)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2,036
2019
(1,484 - 2,700)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.27 (%)
2019, latest modelled
(0.19 - 0.37(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
99 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines